tetano
Editor, Senior Moderator
Cephalalgia
. 2022 Feb 15;3331024211068074.
doi: 10.1177/03331024211068074. Online ahead of print.
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
David Garcia-Azorin[SUP] 1 [/SUP], Almudena Layos-Romero[SUP] 2 [/SUP], Jesús Porta-Etessam[SUP] 3 4 5 [/SUP], Javier A Membrilla[SUP] 6 7 [/SUP], Edoardo Caronna[SUP] 8 9 [/SUP], Alicia Gonzalez-Martinez[SUP] 10 [/SUP], Álvaro Sierra Mencia[SUP] 1 [/SUP], Tomás Segura[SUP] 2 [/SUP], Nuria Gonzalez-García[SUP] 3 4 5 [/SUP], Javier Díaz-de-Terán[SUP] 6 7 [/SUP], Victor J Gallardo[SUP] 9 [/SUP], Ana Beatriz Gago-Veiga[SUP] 10 [/SUP], Alejandro Ballvé[SUP] 8 [/SUP], Javier Trigo López[SUP] 1 [/SUP], María Sastre-Real[SUP] 6 7 [/SUP], Arnau Llauradó[SUP] 8 [/SUP], Ana Cornejo[SUP] 11 [/SUP], Íñigo de Lorenzo[SUP] 6 7 [/SUP], Ángel Guerrero-Peral[SUP] 1 12 [/SUP], Patricia Pozo-Rosich[SUP] 8 9 [/SUP]
Affiliations
Abstract
Background: Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19.
Methods: This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up.
Results: We included 905 patients. Their median age was 51 (IQR 45-65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6-39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5-21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7-18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582-0.737).
Conclusion: The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.
Keywords: COVID-19; Headache disorders; migraine; post-COVID; secondary.
. 2022 Feb 15;3331024211068074.
doi: 10.1177/03331024211068074. Online ahead of print.
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
David Garcia-Azorin[SUP] 1 [/SUP], Almudena Layos-Romero[SUP] 2 [/SUP], Jesús Porta-Etessam[SUP] 3 4 5 [/SUP], Javier A Membrilla[SUP] 6 7 [/SUP], Edoardo Caronna[SUP] 8 9 [/SUP], Alicia Gonzalez-Martinez[SUP] 10 [/SUP], Álvaro Sierra Mencia[SUP] 1 [/SUP], Tomás Segura[SUP] 2 [/SUP], Nuria Gonzalez-García[SUP] 3 4 5 [/SUP], Javier Díaz-de-Terán[SUP] 6 7 [/SUP], Victor J Gallardo[SUP] 9 [/SUP], Ana Beatriz Gago-Veiga[SUP] 10 [/SUP], Alejandro Ballvé[SUP] 8 [/SUP], Javier Trigo López[SUP] 1 [/SUP], María Sastre-Real[SUP] 6 7 [/SUP], Arnau Llauradó[SUP] 8 [/SUP], Ana Cornejo[SUP] 11 [/SUP], Íñigo de Lorenzo[SUP] 6 7 [/SUP], Ángel Guerrero-Peral[SUP] 1 12 [/SUP], Patricia Pozo-Rosich[SUP] 8 9 [/SUP]
Affiliations
- PMID: 35166156
- DOI: 10.1177/03331024211068074
Abstract
Background: Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19.
Methods: This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up.
Results: We included 905 patients. Their median age was 51 (IQR 45-65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6-39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5-21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7-18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582-0.737).
Conclusion: The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.
Keywords: COVID-19; Headache disorders; migraine; post-COVID; secondary.